Insider transactions

Avoro Capital Advisors LLC

CIK 1633313 · last filed 2026-07-27

Avoro Capital Advisors LLC is a corporate insider who has filed 26 SEC Form 4 insider transactions across 6 companies since 2017. The most recent filing, for SCTX, was dated Jul 27, 2026. Across all open-market trades the lifetime net is +$238.7M, making them a net buyer over the disclosed history. The firm reports its address in New York, NY. 43 SEC filings were submitted jointly with Behzad Aghazadeh.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

6

Total Filings

26

Lifetime Open-Market Net

$238.74M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

Filer Profile

Reported Address
110 GREENE STREET
SUITE 800
NEW YORK, NY 10012
Phone
(212) 937-4975
State of Incorporation
DE
Formerly Known As
venBio Select Advisor LLC (2015–2019)
Related Filers
Behzad Aghazadeh — 43 joint filings, latest 2026-07-28
Avoro Ventures LLC — 13 joint filings, latest 2026-07-28
ARENA PHARMACEUTICALS INC — 2 joint filings, latest 2022-02-11
Cerecor Inc. — 2 joint filings, latest 2026-08-14
AGENUS INC — 1 joint filings, latest 2017-02-09
PLP MM LLC — same reported address
Pleasant Lake Offshore Master Fund L.P. — same reported address
Pleasant Lake Onshore GP LLC — same reported address
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
SCTX Director — $16.79 — $0 1 2026-07-27
WHWK Director — $3.70 — $0 3 2026-06-15
Whitehawk Therapeutics, Inc. (AADI) Delisted Director 3,471,752 $2.05 $7.12M $0 4 2025-03-04
CymaBay Therapeutics, Inc. (CBAY) Delisted 10%+ Owner — $32.48 — $0 3 2023-09-14
IMMUNOMEDICS INC (IMMU) Delisted Director 26,267,234 — — $288.76M 13 2020-06-22
Mirati Therapeutics, Inc. (MRTX) Delisted 10%+ Owner 3,800,000 $58.70 $223.06M -$50.02M 2 2019-07-25

Recent Filings

26 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-07-27 SCTX Grant (A) — $0 EDGAR
2026-06-15 WHWK Grant (A) — $0 EDGAR
2026-05-14 WHWK Grant (A) — $0 EDGAR
2025-06-16 WHWK Grant (A) — $0 EDGAR
2025-03-04 Whitehawk Therapeutics, Inc. (AADI) Delisted Grant (A) — $0 EDGAR
2024-06-14 Whitehawk Therapeutics, Inc. (AADI) Delisted Grant (A) — $0 EDGAR
2023-09-14 CymaBay Therapeutics, Inc. (CBAY) Delisted Mixed — $0 EDGAR
2023-06-20 Whitehawk Therapeutics, Inc. (AADI) Delisted Grant (A) — $0 EDGAR
2023-01-30 CymaBay Therapeutics, Inc. (CBAY) Delisted Buy (P) — $0 EDGAR
2022-09-26 Whitehawk Therapeutics, Inc. (AADI) Delisted Grant (A) +3,780,000 $47.25M EDGAR
Showing 1–10 of 26
Page 1 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.